“One of the biggest challenges in technology transfer is to prove to the FDA that what was made in the lab can be made on a large scale to the same quality standards,“ said Lawrence Tamarkin, president and CEO of CytImmune Sciences. Tamarkin presented the first talk of the summer professional development series hosted by the Institute for NanoBioTechnology at Johns Hopkins University. CytImmune Sciences will soon begin Phase 2 clinical trials on a colloidal gold based product that provides targeted and concentrated delivery of a tumor destroying substance.
INBT’s summer professional development series offers students an opportunity to learn from industry representatives on a number of topics related to research and relevant to success in the sciences. Topic range for protecting ones intellectual property to seeking venture capital support,
“These talks allow the students to expand their ideas beyond the focus on their research,“ says Denis Wirtz professor of chemical and biomolecular engineering in the Whiting School of Engineering and associate director of INBT. “It also gives them a better perspective on the ways their research can help society.“
Wirtz added that Tamarkin’s talk highlighted the importance of persistence in research. “Tamarkin emphasized how one must multitask—you must care about the science and manage the public perception of nanoscience as well.“
Talks begin at 11 a.m. and are held in room 303 of Shafer Hall. To attend any of the seminar series talks listed below, please RSVP to Ashanti Edwards via e-mail at email@example.com or by phone at 410-516-6572.
Upcoming professional development talks are:
* July 9
* July 23
* August 6